Home
- Eating Well (or at Least Not terribly) at Fast Food Resturants
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Insulin Articles
Popular Insulin Articles
Highly Recommended Insulin Articles
Email to a Friend
Send a link to this page to your friends and colleagues.
Sitagliptin (Januvia) Lowers Blood Sugar in People With Type 1 Diabetes
Sitagliptin (Januvia) has long been used to reduce blood sugar in people with type 2 diabetes, but a new study indicates that it can do the same for those with type 1 diabetes. Sitagliptin is a DPP-4 inhibitor; that is, it inhibits, or temporarily prevents, the enzyme DPP-4 from destroying a helpful hormone called GLP-1. GLP-1, which is released by the gut when food arrives there from the stomach, lowers blood sugar by causing the release of insulin, reducing the secretion of glucagon, and slowing stomach emptying and nutrient absorption.
Unfortunately, GLP-1 is broken down by DPP-4 after only about a minute of beneficial action. Because GLP-1 could lower blood sugar a lot more if DPP-4 weren't so efficient at destroying it, a DPP-4 inhibitor such as sitagliptin comes in very handy for people with type 2 diabetes. Until now, however, it has not been tested in people with type 1 diabetes.
Now, a small pilot study conducted by Satish Garg, MD, of the University of Colorado, has found that sitagliptin lowers blood sugar in inadequately controlled type 1s as well. The 20 type 1 subjects were given 100 mg of sitagliptin daily or a placebo for four weeks, then switched to the alternate treatment for four more weeks. The sitagliptin lowered their mean blood glucose by about 12 mg/dL and their A1Cs by 0.27%, and they were able to cut their insulin dose by nearly 10 percent during the treatment period.
Dr. Garg plans to firm up his findings with a four-month multicenter study of sitagliptin in 120 type 1 patients.
***
Source:
Categories: A1c Test, Blood Glucose, Blood Sugar, Diabetes, Diabetes, Food, Insulin, Medications, Medications Research, Type 1 Issues, Type 2 Issues, Type 2 Medications
You May Also Be Interested In...
-
Diabetes Health
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
-
Topics
- Diabetic / Diabetes Health
- Type 1 / 1.5 Diabetes
- Type 2 Diabetes
- Blood Glucose / Sugar
- High/Low Blood Sugar / Fast Acting Glucose
- Insulin- Pumps, Pens & Syringes
- Continuous Glucose Monitors, CGM, Infusion Sets
- Type 2 Medications
- Hyperglycemia
- Hypoglycemia
Comments
I have had Type 1 DM for 40 years which is brittle despite close blood glucose monitoring and Intensive Conventional Therapy (ICT) with Apidra and Lantus. My physician started me on a similar private clinical trial of Onglyza (saxaglyptin) for Type 1. My results were positive, reducing blood glucose extremes by 20% or more with no incidents of extreme hypoglycemia.
As an alternative therapy I am now testing Januvia (sitaglyptin), similar to the Dr. Garg's Colorado study. In my case Januvia has also resulted in the 20% improvement in reducing hyperglycemia with rare but mild hypoglycemia episodes. Both I and my Diabetologist have been impressed with these responses.
The initial trial with Onglyza lasted about 8 weeks. I have been in the Januvia trial for five weeks so far. Objectively both sitaglyptin and saxaglyptin have produced positive effects. Subjectively, I seem to prefer Januvia.
We will review the results of both trials at my next physician visit and decide which therapy to use. Hopefully these studies will result in either Onglyza or Januvia will be labelled for use in Type 1 and added to the Medicare formulary.
I would like to see large scale clinical trials to speed the approval process. My family has a history of brittleness in Type 1 unrelated to diet or insulin therapies. These glyptin private trials add a significant tool in improving insulin response and blood glucose management.
I have had Type 1 DM for 40 years which is brittle despite close blood glucose monitoring and Intensive Conventional Therapy (ICT) with Apidra and Lantus. My physician started me on a similar private clinical trial of Onglyza (saxaglyptin) for Type 1. My results were positive, reducing blood glucose extremes by 20% or more with no incidents of extreme hypoglycemia.
As an alternative therapy I am now testing Januvia (sitaglyptin), similar to the Dr. Garg's Colorado study. In my case Januvia has also resulted in the 20% improvement in reducing hyperglycemia with rare but mild hypoglycemia episodes. Both I and my Diabetologist have been impressed with these responses.
The initial trial with Onglyza lasted about 8 weeks. I have been in the Januvia trial for five weeks so far. Objectively both sitaglyptin and saxaglyptin have produced positive effects. Subjectively, I seem to prefer Januvia.
We will review the results of both trials at my next physician visit and decide which therapy to use. Hopefully these studies will result in either Onglyza or Januvia will be labelled for use in Type 1 and added to the Medicare formulary.
I would like to see large scale clinical trials to speed the approval process. My family has a history of brittleness in Type 1 unrelated to diet or insulin therapies. These glyptin private trials add a significant tool in improving insulin response and blood glucose management.
I have had Type 1 DM for 40 years which is brittle despite close blood glucose monitoring and Intensive Conventional Therapy (ICT) with Apidra and Lantus. My physician started me on a similar private clinical trial of Onglyza (saxaglyptin) for Type 1. My results were positive, reducing blood glucose extremes by 20% or more with no incidents of extreme hypoglycemia.
As an alternative therapy I am now testing Januvia (sitaglyptin), similar to the Dr. Garg's Colorado study. In my case Januvia has also resulted in the 20% improvement in reducing hyperglycemia with rare but mild hypoglycemia episodes. Both I and my Diabetologist have been impressed with these responses.
The initial trial with Onglyza lasted about 8 weeks. I have been in the Januvia trial for five weeks so far. Objectively both sitaglyptin and saxaglyptin have produced positive effects. Subjectively, I seem to prefer Januvia.
We will review the results of both trials at my next physician visit and decide which therapy to use. Hopefully these studies will result in either Onglyza or Januvia will be labelled for use in Type 1 and added to the Medicare formulary.
I would like to see large scale clinical trials to speed the approval process. My family has a history of brittleness in Type 1 unrelated to diet or insulin therapies. These glyptin private trials add a significant tool in improving insulin response and blood glucose management.
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register...
Register your Diabetes Health Username here.
Have Your Say...